I joined the German Biotech Industry in 2000 and took a position with Xerion Pharmaceuticals AG, developing therapeutic antibodies on the basis of phage-displayed single chain antibody fragments. I was heading a department of more than 15 employees, were skills in project management, budgeting and leadership were essential. Due to the matrix structure of the operations and the close project based interaction with other departments I could also gain insights into business development and IP issues as well as get first hands-on experience with the requirements for in-vitro and iv-vivo pre-clinical development of antibody therapeutics.
In 2005 I changed to a company concerned with the trea...